Can-Fite publishes study results on canine osteoarthritis drug

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/8/2026

1. SPCX
2. CRNX
3. USO
4. VRTX
5. SPY
6. RIVN
7. WMT
8. CMPS
9. NVDA
10. LMT

Go back to Can-Fite publishes study results on canine osteoarthritis drug

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market

May 18, 2026 7:00 AM EDT

Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract,... More